Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion’s Investigation Reveals ‘Inappropriate’ Conduct, Nothing Illegal

Executive Summary

Alexion’s internal investigation of so-called pull-in sales found no improper financial activity, but will require employee training and amended procedures to avoid further violations of company policies.

You may also be interested in...



Alexion's Defensive Play Poised To Pay Off

The company's long-acting C5 complement inhibitor ALXN1210 demonstrated non-inferiority to Soliris in a Phase III trial, which should help the company defend against anticipated competition to its blockbuster franchise.

Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear

The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.

Alexion’s Soliris Slips Up In Pivotal PROTECT Kidney Transplant Study

A difficult December for Alexion sees a pivotal study of its blockbuster Soliris failing to show any benefit in preventing delayed graft function in kidney transplant patients, an indication for which there are no approved treatments.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel